Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lowe`s Companies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Lowe`s Companies Inc trades at $208.05 (market cap $116.45B). The key difference: Lowe`s Companies Inc is far larger — about 14.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Lowe`s Companies Inc pays a 2.41% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LOW | |
|---|---|---|
Market Cap | $8.04B | $116.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $287.39 |
52-Week Low | $241.71 | $206.62 |
Enterprise Value | $7.85B | $158.20B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Lowe's (LOW) trades at $207.70, down 1.86% on the day, with a bearish technical signal from moving averages but oversold short-term RSI. The company maintains solid profitability with a 7.51% net margin and has beaten EPS estimates for three consecutive quarters. Revenue declined to $83.67B in 2025, though cash flow from operations improved to $9.63B. Recent news highlights Lowe's dividend growth strategy, with the quarterly payout rising to $1.25.
The outlook is mixed: strong analyst consensus (60.79% buy ratings) and a $260.88 price target suggest upside, but technical weakness and high debt levels pose risks. Earnings stability and dividend growth support long-term value, though housing market sensitivity and competitive pressures remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
